Professor and Attending Surgeon, Director of Urologic Oncology Fellowship, University Texas MD Anderson Cancer Center
Urology
Ashish M. Kamat, MB
|
|
Give Review
Ashish M. Kamat, MB works in the field of Urology. He attended Seth G.S. Medical College. He has 7 awards "Compassionate Doctor Award", "Top Doctors in America", "Who's Who in Medicine", "President, International Bladder Cancer Network", "Top Doctors:SE Texas", "Fellow (FACS)" and "Board of Directors". Ashish M. Kamat, MB is a published physician as well. He has 98 publications published. The latest was: Blebbishield emergency program: an apoptotic route to cellular transformation. He accepts Medicare.
Publications
- Natural Compounds Targeting STAT3 Mediated Inflammation.
- Optimal Management of Non-Muscle Invasive Micropapillary Variant Urothelial Carcinoma: Possibility For Missed Chance at Cure?
- Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and ...
- Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
- Outcome of patients with clinically node-positive Bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Expe...
- Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
- Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in Bladder cancer cells.
- Smac Mimetic with TNF-α Targets Pim-1 Isoforms and Reactive Oxygen Species Production to Abrogate Transformation from Blebbishields.
- Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward? ...
- Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for Bladder cancer.
- Immune therapies in non-muscle invasive Bladder cancer.
- Commentary on "Impact of statin use on oncologic outcomes in patients with urothelial carcinoma ofthe Bladder treated with radical cystectomy." da Silva RD, Xylinas E,...
- Commentary on "The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guerin instillation therapy on the quality of life in patients with nonmuscle inva...
- Commentary on "Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive Bladder cancer refractory or intolerant to bacille Calmette-Gue...
- Commentary on "Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed fornonmuscle invasive Bladder cancer." Stern...
- Current concepts-Future needs: The 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012.
- Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive Bladder cancer.
- Assessing the quality of studies on the diagnostic accuracy of tumor markers.
- Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.
- The Effect of Concomitant Carcinoma in Situ on Neoadjuvant Chemotherapy for Urothelial Cell Carcinoma of the Bladder: Inferior Pathologic Outcomes, But No Effect on Su...
- Venous thromboembolism and bleeding risk in Bladder cancer.
- Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive Bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.
- Efficacy and Safety of MCNA in Patients with Non-Muscle Invasive Bladder Cancer at High-Risk of Recurrence and Progression who Have Failed Treatment with Bacillus Calm...
- Pelvic Recurrence Following Radical Cystectomy: A Call to Arms.
- Intravesical Tumor Involvement of the Trigone Is Associated With Nodal Metastasis in Patients Undergoing Radical Cystectomy.
- Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.
- Re: Jarow JP et al.: Clinical trial design for the development of new therapies for non-muscle-invasive Bladder cancer: report of a Food and Drug Administration and A...
- Imputation and subset based association analysis across different Cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.
- Predicting Response to Bacillus Calmette-Guérin: Time to Look Beyond the Ages.
- Micropapillary Bladder cancer: Current treatment patterns and review of the literature.
- Variant histology: role in management and prognosis of nonmuscle invasive Bladder cancer.
- Clinical significance of ureteric 'skip lesions' at the time of radical cystectomy: the M.D. Anderson experience and literature review.
- Anterior Fascial Fixation Does Not Reduce the Parastomal Hernia Rate After Radical Cystectomy and Ileal Conduit.
- Invasive extramammary Paget's disease of the Bladder diagnosed 18 years after noninvasive extramammary Paget's disease of the vulva.
- Clinical-pathologic stage discrepancy in Bladder cancer patients treated with radical cystectomy: results from the national cancer data base.
- Neoadjuvant chemotherapy improves survival of patients with upper Tract urothelial carcinoma.
- Defining and Treating the Spectrum of Intermediate-Risk NMIBC.
- Differential expression of GATA-3 in urothelial carcinoma variants.
- Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial.
- Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition.
- Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive Bladder cancer.
- Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis.
- Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, c...
- Genome-wide association study identifies multiple loci associated with Bladder cancer risk.
- Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives.
- Myths and Mysteries Surrounding Bacillus Calmette-Guérin Therapy for Bladder Cancer.
- Should histologic variants alter definitive treatment of Bladder cancer?
- Comprehensive handbook for developing a Bladder cancer cystectomy database.
- Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson ...
- Gamma-H2AX Level in Peripheral Blood Lymphocytes as a Risk Predictor for Bladder Cancer.
- Refining Patient Selection for Neoadjuvant Chemotherapy Prior to Radical Cystectomy.
- Strategies for optimizing bacillus calmette-guérin.
- Fluid intake, genetic variants of UDP-glucuronosyltransferases, and Bladder cancer risk.
- ZKSCAN3 Is a Master Transcriptional Repressor of Autophagy.
- Genetic variations in regulator of G-protein signaling (RGS) confer risk of Bladder cancer.
- Phase I Trial of Intravesical Recombinant Adenovirus-Mediated Interferon-?2b Formulated in Syn3 for BCG failures in Non-Muscle-Invasive Bladder Cancer.
- A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in loc...
- ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers.
- Blebbishields, the emergency program for Cancer stem cells: sphere formation and tumorigenesis after apoptosis.
- Lymphadenectomy with Robotic Cystectomy.
- Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human Bladder cancer cells.
- Redirecting neutrophils against Bladder cancer cells by BCG and Smac mimetic combination.
- Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo.
- Association of polymorphisms in oxidative stress genes with clinical outcomes for Bladder cancer treated with Bacillus Calmette-Guérin.
- Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with Urethral carcinomas referred to medical oncologists(☆).
- Smac mimetic enables the antiCancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL.
- Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for Bladder cancer: results of a prospective trial.
- Bladder cancer: imperatives for personalized medicine.
- Is repeat transurethral resection needed for minimally invasive t1 urothelial Cancer?
- A genome-wide association study of Bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3.
- Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of Bladder.
- Prospective trial to identify optimal Bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
- The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for Bladder cancer.
- Fluorescence cystoscopy for nonmuscle invasive Bladder cancer: is the honeymoon over for the blue light special?
- The role of radical cystectomy in patients with clinical T4b Bladder cancer.
- Perioperative Outcomes of Laparoscopic Radical Nephroureterectomy and Regional Lymphadenectomy in Patients With Upper Urinary Tract Urothelial Carcinoma After Neoadjuv...
- Robot assisted extended pelvic lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection.
- Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy.
- Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial Cancer cells.
- Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive Bladder cancer.
- Upper Tract urothelial carcinoma: Impact of time to surgery.
- To the Editor: Response to Barlow et al, Urol Oncol 2010.
- High-frequency endoluminal ultrasonography as an aid to the staging of upper Tract urothelial carcinoma: imaging findings and pathologic correlation.
- BCAN Think Tank session 2: Molecular detection of Bladder cancer: the path to progress.
- BCAN Think Tank session 3: Prevention of Bladder cancer.
- Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria.
- Port-site hernias occurring after the use of bladeless radially expanding trocars.
- Activation of nerve growth factor-induced B alpha by methylene-substituted diindolylmethanes in Bladder cancer cells induces apoptosis and inhibits tumor growth.
- Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in Bladder cancer.
- Perioperative intravesical therapy after transurethral resection for Bladder cancer.
- Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against Bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.
- Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human Bladder cancer.
- Cardiac history and risk of post-cystectomy cardiac complications.
- Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial Cancer.
- Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
- Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with Bladder cancer risk in individuals...
- Blebbishield emergency program: an apoptotic route to cellular transformation.
Procedures Preformed
- Cystectomy
- Cystometry
- Cystourethroscopy and TransUrethral Resection of Bladder Neck
- Destruction or Excision of Vaginal Lesions
- View All
Conditions Treated
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- Blood in Urine (Hematuria)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- Compassionate Doctor Award
- Top Doctors in America
- Who's Who in Medicine
- President, International Bladder Cancer Network
- Top Doctors:SE Texas
- Fellow (FACS)
- Board of Directors
Education
-
University of Texas MD Anderson Cancer Center -
West Virginia University -
Seth G.S. Medical College
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1114012895 | |
| NPPES Provider LastName | KAMAT | |
| NPPES Provider FirstName | ASHISH | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Urology | |
| Total Claim Count | 76.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 15.79 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1114012895 |
| Last Name Of The Provider | KAMAT |
| First Name Of The Provider | ASHISH |
| View All |
Similar Doctors
|
|
Dr. Munah J. Hawila, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Goutham Vemana, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wesley A. Mayer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin N. Hendin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin E. Dillon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam B. Hollander, MD |